$RCKT News

Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate

B of A Securities Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $9

Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited

Why Is Rocket Pharma Stock Soaring Friday?

Rocket Pharmaceuticals shares are trading higher after the company announced an FDA accelerated approval for KRESLADI for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I, an ultra-rare, life-threatening pediatric genetic immunodeficiency.

Rocket Pharmaceuticals shares are trading higher after the company announced an FDA accelerated approval for KRESLADI for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I, an ultra-rare, life-threatening pediatric genetic immunodeficiency.

The FDA Approves Rocket Pharmaceuticals' Kresladi For Pediatric Patients With Severe Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals Enters Sales Agreement With Cantor Fitzgerald & Co. For ATM Offering Up To $100M

Rocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Goldman Sachs Maintains Sell on Rocket Pharmaceuticals, Raises Price Target to $3

Rocket Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS results. Also, Cantor Fitzgerald raised its price target on the stock from $8 to $10.

Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10

Rocket Pharmaceuticals Q4 EPS $(0.38) Beats $(0.44) Estimate

Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $8

JP Morgan Downgrades Rocket Pharmaceuticals to Underweight

Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial Officer

Rocket Pharmaceuticals: Q3 Earnings Snapshot